We think of ovarian cancer as high grade serous, clear cell mucinous. So the guidelines start to delve into those but also more rare subtypes, germ cell tumors, carcinoma sarcomas, small cell cancers.
And the guidelines themselves provide a blueprint from which clinicians should look and think about patient care. But it’s also a great text at the back.
This year, we witnessed a number of different things really updating a lot of the medications that we’re using, especially with the multitude of PARP inhibitor, FDA approvals of Niraparib, Rucaparib and Olaparib, and how they’ve really been woven into the care of our patients.
The use of Bevacizumab in patients with recurrent disease, so we’re really, again, providing that foundation for clinicians and how they treat patients, but we’re constantly updating the guidelines in ovarian cancer in the past, one to two to three years.
And I think certainly in the future coming up next few years, we’re gonna see a lot of strides, a lot of treatment advances, and it’s our job to incorporate those advances into the guideline that is digestible and understandable for all types of clinicians who treat ovarian cancer patients.